Shattuck is developing a potentially first-in-class antibody for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in state-of-the-art protein engineering builds on our deep understanding of the tumor necrosis factor (TNF) family of receptors and their unique underlying biology. Shattuck’s lead program, SL-325, is a potentially first-in-class monoclonal antibody antagonist of Death Receptor 3 (DR3), the receptor for TL1A, designed to achieve deeper and more durable blockade of the clinically validated TL1A/DR3 pathway.
About Us
Shattuck’s mission is to use novel approaches to protein engineering to deliver drugs that improve the lives of patients. At the core of that mission is a company that brings together leading scientists, drug manufacturers, physicians, and other professionals to challenge conventional thinking and develop transformational medicines that measurably improve the lives of patients.
Our Approach
We believe that developing specialized therapeutics to activate or inhibit TNF receptors can address significant unmet medical needs in oncology and autoimmune/inflammatory diseases. The development of TNF receptor agonists has necessitated the creation of rigorous tools and expertise to interrogate TNF receptor inhibitors, which has been a highly successful therapeutic approach in a number of autoimmune/inflammatory diseases. We believe in combining a strong technological and scientific foundation with deep professional expertise to drive the execution of our broader corporate mission.
